Disease/Infection News

RSS

Chilblains and COVID-19

The current COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is primarily a respiratory infection, though the majority of cases are asymptomatic or mild disease. However, other manifestations are also being reported, such as gastrointestinal features, neurological signs, and skin symptoms. A new study published online in the journal JAMA Dermatology in June 2020 examines the possibility that chilblains could be a manifestation of COVID-19.

26 Jun 2020

Genes associated with SARS-CoV-2 human lung cell infection

Now, a new study published on the preprint server bioRxiv in June 2020 attempts to make sense of this data to identify viral genes that are explicitly expressed in the cells infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could help reveal new therapeutic targets.

26 Jun 2020

SARS-CoV-2 has been evolving for at least 7 years

The burning question is how novel viruses acquire the ability to recognize, bind to and enter human cells for the first time – whether this is dependent only on viral proteins recognizing host cell proteins, or adaptations in other viral processes that allow replication in a human host.

25 Jun 2020

Race, rurality play huge role in Georgia areas hardest hit by COVID-19

While counties in populous metropolitan Atlanta had the highest number of COVID-19 cases in the initial weeks following Georgia's first reported case, it was rural Southwest Georgia counties, with a higher number of black residents and lower number of ICU beds, experiencing the highest rates of infection and death per capita, investigators report.

25 Jun 2020

Study: People with IDD living in residential group homes more likely to die from COVID-19

A new study published recently in ScienceDirect by researchers from Syracuse University and SUNY Upstate Medical University shows that people with intellectual and developmental disabilities living in residential group homes are more likely to be diagnosed with COVID-19 and die from the virus than those without IDD.

25 Jun 2020

Entos Pharmaceuticals selects two lead DNA vaccine candidates for COVID-19

Entos Pharmaceuticals, a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine from its prototyping program launched at the onset of the global COVID-19 pandemic.

25 Jun 2020

Dysregulated inflammation in severe COVID-19

The continuing COVID-19 pandemic has so far caused 9.58 million cases and more than 488,000 deaths within just six months. The spectrum of disease is broad, from completely asymptomatic cases to critical illness ending in death. Now, a new paper by researchers from Yale University and published on the preprint server medRxiv* in June 2020 identifies an imbalance in immunological response that is linked to poor outcomes and early biomarkers that may help predict the course of the disease.

25 Jun 2020

Researchers study unique needs of caregivers of persons with ADRD during COVID-19

Sixteen million family members in the U.S. are caregivers for the more than 6 million people living with Alzheimer's Disease and Related Dementias (ADRD).

25 Jun 2020

Pixatimod is active in lab studies against SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulating the world has caused over 9.6 million cases and over 490,000 deaths as of June 26, 2020. With neither an effective vaccine nor therapeutic drug yet available, intensive and widespread research is ongoing to develop a pharmacological intervention that will halt the global pandemic.

25 Jun 2020

Researchers develop unique saliva-based test for COVID-19 detection

University of Saskatchewan researchers are part of two COVID-19-related projects awarded major federal funding today--one to develop a unique saliva-based test for COVID-19 detection and the other to track COVID-19 incidence rates among Canadian dentists.

25 Jun 2020

Biological therapy may decrease the risk of severe COVID-19

A recent observational study by Spanish researchers, currently available on the medRxiv preprint server, suggests that patients with immune-mediated diseases who receive biological therapy may have a lower risk for severe manifestations of coronavirus disease (COVID-19).

25 Jun 2020

SARS-CoV-2 can replicate in human pediatric gastric organoids

A diverse research group from the United Kingdom, Italy, China, and Australia established a first expandable human gastric organoid culture across fetal developmental stages, supporting the hypothesis that fetal tissue seems to be much less susceptible to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection – especially in the early stages of development.

25 Jun 2020

Physical and mental health impacts of COVID-19 in northern Dutch provinces

Researchers at the University Medical Center Groningen, in the Netherlands, have described preliminary results from the Lifelines COVID-19 Study, where participants living in northern Dutch provinces self-report their experiences during the coronavirus disease 2019 (COVID-19) pandemic and any effects on their physical and mental health.

25 Jun 2020

Global research community revises WHO COVID-19 research priorities

Researchers have described the results of a survey aiming to determine the current applicability of the World Health Organization’s COVID-19 Research Roadmap and whether there are new priorities that should be focused on at this point in time during the pandemic.

25 Jun 2020

USask researchers receive $900,000 to help strengthen Canada's rapid response to COVID-19

The Canadian Institutes of Health Research has awarded three University of Saskatchewan research teams a total of $900,000 to help strengthen Canada's rapid response to the COVID-19 pandemic which had killed more than 450,000 people worldwide.

25 Jun 2020

Emory launches COVIDVu study to understand the extent of epidemic across the U.S.

Researchers from Emory University's Rollins School of Public Health were awarded a $6.6 million grant from the National Institutes of Health to launch COVIDVu, a national study that will use home tests to develop estimates of the current number of COVID-19 infections and persons with antibody response nationally and across seven heavily impacted states.

25 Jun 2020